Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
A recent study with the DPP-IV inhibitor Linagliptin showed an improvement in the urinary
albumin creatinine ratio in patients with diabetic nephropathy. Gutzwiller et. Al. have shown
that GLP-1 increases renal Na secretion and inhibits renal H secretion, further indicating
some direct renal effects of GLP-1.
Therefore, it seems likely that treatment with the DPP-IV inhibitor Linagliptin evolves
several beneficial effects on microvascular and endothelial function beyond glucose control
which most probably have an impact on the progression of renal and retinal microvascular
disease.
The objective of this trial is to investigate the effect of Linagliptin in comparison to
placebo on the UACR in patients with high blood pressure and an increased albumin excretion.
Numerous, equivalent endothelial, renal, and retinal parameters serve as objectives of the
study. All study parameters will be handled in an exploratory sense for the generation of
models to further discuss the role of DPP-IV inhibition on renal and retinal physiology.
Phase:
Phase 3
Details
Lead Sponsor:
ikfe-CRO GmbH
Collaborators:
Ikfe GmbH MLM Medical Labs GmbH MLM Medical Labs Mönchengladbach